Organon and Braincells to collaborate in discovery and development of CNS drugs
Organon, the human health care business unit of Akzo Nobel , and BrainCells Inc. (BCI) announced they will collaborate in the discovery and development of drugs for the treatment of central nervous system (CNS) disorders.
BCI will use its proprietary technology in the area of neurogenesis - the process by which pre-existing stem cells in the adult human brain produce new brain tissue, including neurons - to identify neuroscience applications for compounds formerly in the Organon clinical-stage pipeline. When BCI determines the therapeutic utility for a drug candidate, the companies will work together to develop and reposition the drug for its new use.
"We can bring new life to compounds that might otherwise sit on the shelf," said James A. Schoeneck, BCI's CEO. "The collaboration with Organon is a validation of our drug selection technology and development capabilities. By focusing on compounds that have already been tested for safety in the clinic, we can accelerate drug development while minimizing risk."
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.